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Polymerase- (POLG) is a major human disease gene and may account for up to 25% of all mitochondrial diseases in the UK
and in Italy. To date, 4150 different pathogenic mutations have been described in POLG. Some mutations behave as both
dominant and recessive alleles, but an autosomal recessive inheritance pattern is much more common. The most frequently
detected pathogenic POLG mutation in the Caucasian population is c.1399G4A leading to a p.Ala467Thr missense mutation in
the linker domain of the protein. Although many patients are homozygous for this mutation, clinical presentation is highly
variable, ranging from childhood-onset Alpers-Huttenlocher syndrome to adult-onset sensory ataxic neuropathy dysarthria and
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ophthalmoparesis. The reasons for this are not clear, but familial clustering of phenotypes suggests that modifying factors may
influence the clinical manifestation. In this study, we collected clinical, histological and biochemical data from 68 patients
carrying the homozygous p.Ala467Thr mutation from eight diagnostic centres in Europe and the USA. We performed DNA
analysis in 44 of these patients to search for a genetic modifier within POLG and flanking regions potentially involved in the
regulation of gene expression, and extended our analysis to other genes affecting mitochondrial DNA maintenance (POLG2,
PEO1 and ANT1). The clinical presentation included almost the entire phenotypic spectrum of all known POLG mutations.
Interestingly, the clinical presentation was similar in siblings, implying a genetic basis for the phenotypic variability amongst
homozygotes. However, the p.Ala467Thr allele was present on a shared haplotype in each affected individual, and there was no
correlation between the clinical presentation and genetic variants in any of the analysed nuclear genes. Patients with mito-
chondrial DNA haplogroup U developed epilepsy significantly less frequently than patients with any other mitochondrial DNA
haplotype. Epilepsy was reported significantly more frequently in females than in males, and also showed an association with
one of the chromosomal markers defining the POLG haplotype. In conclusion, our clinical results show that the homozygous
p.Ala467Thr POLG mutation does not cause discrete phenotypes, as previously suggested, but rather there is a continuum of
clinical symptoms. Our results suggest that the mitochondrial DNA background plays an important role in modifying the disease
phenotype but nuclear modifiers, epigenetic and environmental factors may also influence the severity of disease.
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Abbreviation: SANDO = sensory ataxic neuropathy, dysarthria and ophthalmoparesis
Introduction
The POLG gene codes for the catalytic subunit of polymerase ,
the only DNA polymerase found within mitochondria (Ropp and
Copeland, 1996; Chinnery and Zeviani, 2008). During the past
10 years, mutations in POLG have been identified in a wide
range of mitochondrial diseases, including progressive external
ophthalmoparesis (Van Goethem et al., 2001), Alpers/
Alpers-Huttenlocher syndrome (Naviaux and Nguyen, 2004),
adult-onset spinocerebellar ataxia (Van Goethem et al., 2003,
2004), parkinsonism and premature ovarian failure (Luoma
et al., 2004). Although POLG is a nuclear gene, clinical symptoms
are related to a secondary impairment of mitochondrial DNA
(accumulation of multiple mitochondrial DNA deletions,
decreased mitochondrial DNA copy numbers or somatic mitochon-
drial DNA point mutations) in the affected tissues. It is becoming
clear that POLG is a major human disease gene, possibly accounting
for up to 25% of all patients with mitochondrial diseases in the UK
and in Italy (Chinnery and Zeviani, 2008). To date, 150 patho-
logical mutations have been identified in this gene (http://tools.
niehs.nih.gov/polg/). POLG mutations may behave as both domin-
ant and recessive alleles and multiple (43 or 4) mutations may occur
in single individuals, further complicating the genetic diagnosis of
POLG-related disease (Horvath et al., 2006). In addition to clearly
pathogenic mutations, polymorphic genetic variants may also
modulate the phenotype (Luoma et al., 2005).
The two most frequent pathogenic POLG mutations in
Caucasians are c.1399G4A (p.Ala467Thr) and c.2243G4C
(p.Trp748Ser) (Hakonen et al., 2005, 2007). In one study, both
mutations appeared to reside on a common ancient European
haplotype in patients throughout Europe, Australia, New Zealand
and the USA (Hakonen et al., 2007). The associated alleles have
spread to populations of European descent with carrier frequencies
up to 1% in several of them, therefore representing a common
cause of ataxia and Alpers’ syndrome in the Western world
(Hakonen et al., 2007).
It has been shown that the p.Trp748Ser mutation is one of the
most common causes of inherited ataxia in Finland and Norway
(Hakonen et al., 2005). Despite the fact that affected individuals
had the identical homozygous p.Trp748Ser mutation, the pheno-
types in this study were surprisingly heterogeneous and typically
included ataxia, peripheral neuropathy, dysarthria, mild cognitive
impairment, involuntary movements, psychiatric symptoms and
epileptic seizures (Hakonen et al., 2005).
Except for the Scandinavian population discussed above, the
p.Ala467Thr mutation seems to be the most common non-
synonymous disease-causing POLG mutation worldwide (Luoma
et al., 2004; Horvath et al., 2006; Chinnery and Zeviani, 2008;
Blok et al., 2009). POLG containing the p.Ala467Thr mutation has
a polymerase activity that is only 4% of the wild-type enzyme
(Chan et al., 2005; Luoma et al., 2005), most likely due to
reduced DNA binding and to impaired initiation of DNA strand
elongation by modified interaction with the 55 kD accessory sub-
unit (POLG2). The p.Ala467Thr mutation is generally considered
recessive, but it was suggested that p.Ala467Thr may give rise to a
mild dominant phenotype causing late-onset ptosis (Luoma et al.,
2005). Patients homozygous for p.Trp748Ser also have variable
clinical presentation, although published phenotypes fall into sev-
eral discrete clinical groups, including childhood-onset severe epi-
lepsy and liver failure (Alpers-Huttenlocher syndrome), and adult-
onset sensory ataxic neuropathy, dysarthria and ophthalmoparesis
(SANDO). The suggestion of familial clustering of these pheno-
types implicates additional genetic or shared environmental factors
influencing the expression of the clinical phenotype (Tzoulis et al.,
2006; Cohen and Naviaux, 2010). However, there have been no
large-scale multi-national studies of patients harbouring
p.Ala467Thr or p.Trp748Ser, and our understanding of the pheno-
typic spectrum is based on small case series and isolated case
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reports, with publication bias favouring the description of different
phenotypes.
Previously, some European mitochondrial DNA haplogroups
have been correlated with clinical conditions caused by mitochon-
drial DNA mutations (Hudson et al., 2007). The functional conse-
quences of mitochondrial DNA genetic backgrounds (haplotypes,
haplogroups) have been demonstrated by both disease association
and in vitro studies (Wallace, 2005, 2008; Hudson et al., 2007).
We collected clinical data and DNA samples from 68 patients
from 58 families homozygous for the p.Ala467Thr POLG mutation
and provide the first comprehensive phenotypic description of this
common genetic disease, with a view to defining the cause of the
variable clinical presentation of this single homozygous mutation
through the detailed characterization of relevant nuclear genes
and the mitochondrial genome.
Patients and methods
We contacted eight national diagnostic centres in Europe and the USA,
allowing the identification of 68 patients from 58 families, homozy-
gous for the p.Ala467Thr mutation (Supplementary material and
Table 1). These patients were prospectively collected over a 10-year
period (2001–11), and follow-up information was available for all pa-
tients. The following patients were reported previously: five Dutch
patients (Blok et al., 2009), two Belgian siblings (Van Goethem
et al., 2004), one isolated Belgian patient (Van Goethem et al,
2003), two UK patients (Stewart et al., 2009) and one German patient
(Horvath et al., 2006).
Using a standardized questionnaire, we collected clinical data on
age, gender, case histories, clinical presentation, examination findings
including skeletal muscle biopsy and analysed them as a group
(Supplementary material).
Genetic analysis
Genomic DNA of 44 patients was available for further studies. The
analyses for mitochondrial DNA deletions and depletion and sequen-
cing of the 22 coding exons and flanking intronic regions of POLG
were performed in the diagnostic laboratories. The predicted promoter
region of POLG was determined from the Transcriptional Regulatory
Element Database (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process
=home), and direct Sanger sequencing of this entire promoter was
performed (Supplementary material). Sequencing of the genes
POLG2, PEO1 and ANT1 was performed by standard methods using
intronic primers (Supplementary material). Microsatellite marker ana-
lysis of the POLG locus was performed using four markers (D15S979,
D15S1045, D15S202, D15S127) closely flanking the POLG gene on
chromosome 15 by standard methods. The rationale behind studying
microsatellite markers and not single nucleotide polymorphisms was
that microsatellite markers evolve faster, and thus might tag an
allele that alters the phenotype, whereas ancient single nucleotide
polymorphisms may only show a core haplotype. The mitochondrial
DNA haplogroup in the 44 samples were determined by PCR amplifi-
cation and restriction fragment length polymorphism analysis using a
standard algorithm (Supplementary material).
Statistical analysis
To assess the relationship between the clinical and genetic findings,
logistic regression table and Fisher’s exact tests (SPSS Statistics 17.0)
were performed. The associations between the microsatellite marker
length and phenotype were assessed by t-test and by the
non-parametric Wilcoxon rank sum test with continuity correction,
carried out in using the R statistical package. We compared age of
onset with clinical symptoms (e.g. epilepsy, liver failure, ataxia, neur-
opathy) using Kaplan–Meier survival curves, and the statistical signifi-
cance was calculated by the Mantel–Cox test.
Results
Clinical presentation
The clinical presentation of the 68 patients is summarized in the
Supplementary material. The phenotypes did not fall into discrete
groups, but formed a continuous spectrum of disease. Age at
onset in our cohort varied from 2–40 years (mean, 18.8  9.6
years) (Table 2). Comparing disease onset and the presence or
absence of clinical symptoms, we found that in the presence of
epilepsy, the age of disease onset was significantly
(P = 2.6  104) lower (15.9  8.1 years, n = 41) than in patients
without epilepsy (24.2  9.3, n = 27). Ataxia and neuropathy
were both associated with a later onset of disease (Tables 1–4).
In general, patients presenting at a younger age tended to have
epilepsy and hepatopathy, thus resembling patients with com-
pound heterozygous POLG mutations, whereas older patients
tended to have ataxia and peripheral neuropathy (Fig. 1).
There was a striking association of epilepsy and mortality. Of
the 41 patients who had epilepsy, 24 (59%) died either following
a severe episode of epileptic encephalopathy (n = 13) or because
of liver failure (n = 11) and most deaths occurred either in the late
second and third or in the fifth and sixth decades. In contrast, of
the 27 patients without epilepsy, only one patient died (age 46
years), suggesting that these patients have a better prognosis. We
also observed a significant difference in the presence or absence of
epilepsy between genders (female predominance, P50.025)
(Fig. 2A and B). Because of the low number of patients, we
have not subclassified them based on the different types of
epilepsy.
Liver failure occurred exclusively in patients with epilepsy.
Nineteen out of 41 patients with epilepsy developed liver prob-
lems, including abnormal liver enzymes and liver enlargement
(46%); this was fatal in 11 cases, and in six cases, it became
fatal after sodium valproate therapy (Table 3). These data indicate
Table 1 Number of patients from the different centres
presented with the major phenotypes
Phenotype UK G NL1 NL2 B N F USA
Alpers 1 6 4 2 1 0 0 0 14
SANDO 4 6 2 7 3 1 2 2 27
Mixed 8 2 3 3 4 5 1 1 27
13 14 9 12 8 6 3 3 68
B = Belgium; F = France; G = Germany; N = Norway; NL = Netherlands.
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Figure 1 Kaplan–Meier hazard curves of ‘age of onset’ versus phenotype (i.e. epilepsy Y/N) in our cohort of 68 patients (n = 68) analysed
by Log-Rank test (Mantel–Cox). Epilepsy and especially liver dysfunction are clearly correlated with younger age (both significant,
P40.05), but neuropathy and ataxia have ‘crossed lines’ (P50.05). Number of patients in each category are as follows: epilepsy—with
(yes) n = 41, without n = 27; ataxia—with n = 58, without n = 10; neuropathy— with n = 54, without n = 14; liver failure—with n = 19,
without n = 49.
Table 2 Clinical presentation, age of onset and death in 68 patients homozygous for p.Ala467Thr
Symptom Alpers SANDO Mixed
Epilepsy +  +
Neuropathy  + +
Ataxia  + +
14 patients (20%) 27 patients (40%) 14 patients (20%)
Age of onset 13.2  5.6 years 24.2  9.3 years 17.2  8.9 years
Age at death 18.1  7.5 years (n = 9) 46 years (n = 1) 40  14.4 years (n = 15)
Death rate 9/14 (70%) 1/27 (3.7%) 15/27 (55%)
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that the unfavourable prognosis associated with epilepsy was not
always related to valproate toxicity, as 5 out of 11 patients who
developed fatal liver failure did not receive valproate therapy.
Muscle histology revealed ragged red fibres or cytochrome c
oxidase–deficient fibres in 91% of the patients (31/34), a mito-
chondrial respiratory chain defect in 54% (13/24), multiple mito-
chondrial DNA deletions in 60% (18/30), whereas mitochondrial
DNA depletion was present in only 13% of the patients (2/16)
(Table 4). Histological, biochemical and genetic analysis of skeletal
muscle did not show a correlation with disease severity. However,
histological abnormalities, biochemical respiratory chain deficiency
and multiple mitochondrial DNA deletions were more frequent in
older patients. All patients with progressive external ophthalmo-
paresis and/or myopathy had abnormal muscle histology.
Figure 2 (A) Females are more likely to develop epilepsy. (B) The presence or absence of epilepsy in males and (C) females is shown.
Table 3 Summary of the clinical presentation of the homozygous p.Ala467Thr in our cohort
Clinical presentation Present Age Absent Age
Family history 35 (51%) N/A 33 (49%) N/A
Ataxia 58 (85%) 19.7  9.76 10 (15%) 15  5.0
Epilepsy 41 (62%) 15.9  8.1 27 (38%) 24.2  9.3
Neuropathy 54 (79%) 20.4  9.68 14 (21%) 13.92  6.52
PEO 29 (43%) Ragged red fibres
39 (57%)
Myopathy 14 (21%) 54 (79%)
SLE 16 (24%) 52 (76%)
Extrapyramidal 6 (9%) 62 (91%)
Liver involvement 19 (28%) 49 (72%)
Cardiac symptom 2 (3%) 66 (97%)
PEO = progressive external ophthalmoparesis; SLE = stroke-like episodes.
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Interestingly, the clinical presentation was similar in siblings from
seven of eight families. Clinical presentation and age at onset of
patients within these families are summarized in Table 5.
Although we observed a continuum of clinical features across
the group, we subdivided the patients into ‘extreme phenotypes’
to facilitate our search for potential genetic modifiers
(Supplementary material), and allow for a comparison of allele
and haplotype/haplogroup frequencies. These groups were
Alpers (-Huttenlocher) syndrome (defined by the presence of an
epileptic encephalopathy without evidence of a peripheral neur-
opathy); SANDO (defined by the presence of sensory-ataxia,
neuropathy, dysarthria and ophthalmoparesis without epilepsy);
patients presenting with an intermediate phenotype, including epi-
lepsy, ataxia and peripheral neuropathy (intermediate group).
Based on these criteria, 14 patients presented with Alpers
(-Huttenlocher) syndrome, 27 patients with SANDO and 27 pa-
tients showed a combination of epilepsy, ataxia and sensory-
axonal neuropathy (intermediate group).
Heterozygous carriers of the p.Ala467Thr mutation were not
investigated in this study, but family histories of the homozygous
patients did not suggest that heterozygous carriers had clinical
symptoms.
Genetic variants in POLG including the
promoter region
No additional polymorphic variants were detected in the POLG
coding region compared with the reference sequence; this is con-
sistent with a common haplotype and single founder mutation.
Many single nucleotide polymorphisms have been reported in
POLG, some of them with high frequency in Caucasian popula-
tions (http://tools.niehs.nih.gov/polg/, Supplementary material).
In one of the diagnostic laboratories involved in this study
Medical Genetics Center, diagnostic sequencing of the entire
coding region of POLG with flanking intronic sequences showed
that 620 out of 897 (70%) patients from independent families
carried different single nucleotide polymorphisms in POLG, indi-
cating that the wild-type sequence is much less frequent than the
presence of single nucleotide polymorphisms (data not shown). In
addition to the POLG allele containing p.Ala467Thr, a few other
alleles containing single pathogenic mutations (p.Gly848Ser,
p.Thr251Ile/p.Pro587Leu, p.Ala862Thr, p.Arg964Cys,
p.Ser764Arg, p.Ser1104Cys, p.Lys1191Asn) lacked any other
single nucleotide polymorphisms. Sequencing of the predicted
297 bp promoter region of POLG (Transcriptional Regulatory
Element Database, Genomatix software) revealed only one re-
ported single homozygous nucleotide polymorphism
(g.4650T4A, National Center for Biotechnology Information
(NCBI) rs6496572, Minor allele Frequency/minor allele count
A = 0.006/14) that was found in all homozygous p.Ala467Thr pa-
tient samples, indicating that this single nucleotide polymorphism
is part of the original POLG haplotype.
Table 5 The clinical presentation of the homozygous p.Ala467Thr POLG mutation in siblings
Family Clinical presentation Age of onset Current age/died Symptoms
E A N M L
Family A SANDO 10 37  + +  
SANDO 15 33  + +  
Family B SANDO 22 37  + + + 
SANDO 20 37  + + + 
Family C SANDO 20 42  + + + 
ALPERS 20 26† +    +
Family D Intermediate 9 18† + + +  +
Intermediate 19 35 + + +  
Family E Intermediate 12 44 + + + + 
Intermediate 14 20† + + +  
Intermediate 13 17† + + +  +
Intermediate 16 44 + + +  
Family F Intermediate 15 44† + + + + 
Intermediate 8 47† + + + + +
Family G Intermediate 17 53† + + + + +
Intermediate 5 55† + + + + 
Family H SANDO 15 23 + + + + 
SANDO 25 30 + + + + 
E = epilepsy; A = ataxia; N = neuropathy; M = myopathy; L = liver problem; † = died.
Table 4 Summary of the muscle biopsy results of the
homozygous p.Ala467Thr in our cohort
Muscle biopsy Present Absent Not
analysed
RRF 31 (91%) 3 (9%) 34
RC activity 13 (54%) 11 (46%) 44
mtDNA deletions 18 (60%) 12 (40%) 38
mtDNA depletion 2 (13%) 14 (87%) 52
mtDNA = mitochondrial DNA; RC = respiratory chain; RRF = ragged red fibres.
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Sequencing of POLG2, PEO1 and ANT1
Two known intronic and two exonic single nucleotide polymorph-
isms have been found in POLG2: c.1292  31T4G (rs9908620) in
nine patients, c.1292  146C4T (rs9908927) in seven patients, a
non-synonymous single nucleotide polymorphism (c.505G4A,
p.Ala169Thr, rs1427463) in eight patients and the synonymous
c.1269C4T, p.Ser423Ser (rs61733782) in six patients. The occur-
rence of these variants in our cohort was not statistically different
in patients with different clinical presentations and was a fair rep-
resentation of the frequency in normal Caucasian controls
(Supplementary material). No correlation was detected between
the missense variant c.505G4A, p.Ala169Thr and clinical pheno-
type (chi-square test, P40.05).
In 30% of patients (12 patients), we detected three known
intronic single nucleotide polymorphisms in PEO1 (c.1593-
5C4T: rs3740485, c.1593-3T4C: rs3740486, c.1734  16C4A:
rs3740487) and one non-synonymous single nucleotide poly-
morphism, p.Val368Ile (rs17113613) in a single patient. One
intronic single nucleotide polymorphism was found in ANT1,
c.-25G4A (rs3733652). No significant correlation (2 test,
P40.05) was observed between these single nucleotide poly-
morphisms and clinical severity, and the representation of these
single nucleotide polymorphisms in our cohort was similar to that
in normal controls (Supplementary material). There was no correl-
ation between clinical presentation and number of single nucleo-
tide polymorphisms (mutational burden), suggesting no additional
effect on the phenotype of more single nucleotide polymorphisms
in one gene or in different genes. Detailed statistical evaluation is
outlined in the Supplementary material. As the analysis of these
three nuclear genes interacting with POLG on mitochondrial DNA
maintenance did not show any association with clinical presenta-
tion, we did not complete the analysis of the other mitochondrial
DNA maintenance genes, which have a more distant interaction
with POLG on mitochondrial DNA.
Correlation with chromosomal
haplotype
Using both genetic and clinical data, we compiled a schematic
diagram (Fig. 3) to show the chromosomal haplogroups together
Figure 3 Schematic representation of chromosome 15 showing the position of POLG gene in the middle with flanking markers. Below we
illustrate the location of the POLG promoter region and the tested markers. The table shows the manually reconstructed haplotypes for
individual patients. The -1 and -2 variants in each marker mean the two alleles. Patients with matching haplotypes are blocked. The table
also demonstrates the clinical aspects of each patient in respect to their haplotype. A = Alpers, S = SANDO, M = intermediate. Age of
onset: O =416 years; U =415 years. N = none; FV = fatal valproate; F = liver fatal; L = liver non-fatal; O = other; U = UK;
G = Germany; B = Belgium; N = The Netherlands.
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and to compare these data to the phenotype. We also looked for
correlation with age at onset of symptoms (515 years/
416 years). Analysis of the four markers showed increasing vari-
ability, especially for D15S979 and D15S127 further upstream or
downstream from POLG (Fig. 3). There are no population fre-
quency data available for the microsatellite markers used in this
study, but the presence of homogeneous blocks in the proximity
of POLG in the face of high variability in these markers further
downstream or upstream is in keeping with a single common
European ancestor for the p.Ala467Thr mutation, as suggested
previously (Luoma et al., 2005). Comparison of the chromosomal
haplotype-blocks with age at onset and phenotype showed only
one possible association involving one of the four polymorphic
repeat regions (D15S127) and epilepsy. Comparing the distribu-
tion of markers in the epilepsy cases versus the non-epilepsy cases
showed that the numbers of the D15S127 repeats was lower in
the epilepsy cases than in controls (P50.00033, Fig. 4), suggest-
ing that closer genealogical relationship may have an effect on the
development of epilepsy. There are no population frequency
data known for this marker, therefore we cannot predict whether
the low repeat number is frequent in normal population or part of
the ancient POLG haplotype. This marker is also not located
within a known gene. None of the other three markers were sig-
nificant at the 0.05 level (Fig. 4B). We repeated the statistical
tests using the non-parametric Wilcoxon test and found the
same result with only D15S127 significantly associated with epi-
lepsy (P = 0.00032).
Correlation with mitochondrial DNA
haplogroups
We used the Fisher’s exact test to compare mitochondrial DNA
haplogroup with the following major symptoms: epilepsy, ataxia,
neuropathy, progressive external ophthalmoparesis, myopathy,
stroke, cardiac involvement and liver involvement. Haplogroup
Figure 4 (A) The figure shows the analysis for association of the D15S127 marker and epilepsy. (B) The boxes to the right give the mean,
median and the inter-quartile ranges for each data set. The whiskers on the boxes are the 95% confidence intervals for the data range.
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frequencies were similar to the European population controls
(Fig. 5). Mitochondrial DNA haplogroup U alone demonstrated a
significant negative association with epilepsy (P50.025), implying
that mitochondrial DNA haplogroup U may protect against the
development of epilepsy. For analysis, we combined the hap-
logroups into reasonable categories based on the phylogenetic
tree. We chose to use ‘H  V’ (n = 16), ‘U  K’ (n = 12), ‘J  T’
(n = 7) and ‘W  X’ (n = 5). Our data suggest that the ‘U  K’
haplogroup is protective against epilepsy (3/12, P = 0.005 by
Fishers exact test). The effect size here is large, giving a rather
good P-value despite the small sample size (Fig. 5). This P-value is
low enough to remain significant even with a multiple testing
correction for the four haplogroup sets. We note that all three
‘U  K’ individuals with epilepsy were female, and gender is, in
fact, a significant factor.
Discussion
The high clinical variability in patients carrying different POLG
mutations is well known and has been illustrated in numerous
publications during the past 10 years (Van Goethem et al.,
2001, 2003, 2004; Luoma et al., 2004; Naviaux and Nguyen,
2004; Horvath et al., 2006; Chinnery and Zeviani, 2008).
Although it was originally suggested that the location of the mu-
tation in different protein domains (exonuclease, linker, polymer-
ase) may influence the clinical presentation (Horvath et al., 2006;
Stumpf and Copeland, 2011), recent studies in numerous patients
do not support this hypothesis (Milone et al., 2011; Tang et al.,
2011). However, a recent study modelled patient mutations onto
POLG crystal structure and noted that in 3D, the mutations fall
into specific functional domains, and specific combinations of
Figure 5 (A) Stacked graph is showing the mitochondrial DNA haplogroup as a % of the patient population and the phenotype as a %
of individual mitochondrial DNA haplogroups. (B) Population frequency data for mitochondrial DNA haplogroups from Mitomap.
(C) Incidence of epilepsy in our patient cohort in association with the combined and individual mtDNA haplogroups.
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mutations led to specific phenotypes (Euro et al., 2011).
Evaluation of 92 patients with two mutant POLG alleles showed
that these exhibited a wide spectrum of clinical symptoms (Tang
et al., 2011). Seizures, hepatopathy and lactic acidosis were pre-
dominant in younger patients, whereas patients with adult-onset
disease had a higher percentage of myopathy, sensory-ataxia and
ophthalmoparesis (Tang et al., 2011). Our data show similar
age-related trends and indicate that clinical presentations can be
almost as diverse in patients carrying the homozygous
p.Ala467Thr mutation, as in compound heterozygous cases, sug-
gesting that the major determinant of clinical severity is not the
location or type of mutation, but other genetic or epigenetic fac-
tors. Our aim in this study was to search for these factors.
Patients that were homozygous for the p.Ala467Thr presented
with epilepsy and liver involvement in young age, supporting the
clinical observation made earlier that epilepsy is usually the first
clinical sign of POLG deficiency when the disease manifests in
childhood (Isohanni et al., 2011). Those who developed epilepsy
in their teens also had poor prognosis because of progressive epi-
leptic encephalopathy leading to stepwise decline in motor and
cognitive functions. There was another peak of epileptic enceph-
alopathy in adult patients in their forties or fifties, which deter-
mined clinical course and prognosis of disease in these. The
manifestation of severe epileptic encephalopathy in teenage
years suggests a possible modifying effect of hormonal changes,
but there was no exacerbation of clinical symptoms in pregnancy.
Alcohol or toxic substances may also act as triggers of acute en-
cephalopathy, but our information was not sufficient to explore
this association.
The types of epilepsy in POLG deficiency and in MELAS (mito-
chondrial encephalomyopathy, lactic acidosis and stroke-like epi-
sodes) show similarities in their clinicopathological evolution, in
post-mortem pathological features (Tzoulis and Bindoff, 2008;
Bindoff, 2011) and in MRI. Post-mortem studies suggested that
status epilepticus is the result of cortical damage resulting from
energy failure (Tzoulis and Bindoff, 2008; Bindoff, 2011). Liver
failure, another important prognostic factor, was also associated
with epilepsy, and this was exacerbated in patients receiving
sodium valproate, which led to death in six of our cases.
Interestingly, liver problems were not reported in any of the pa-
tients without epilepsy, although liver failure was not always trig-
gered by valproate therapy. If epilepsy did not develop,
homozygous p.Ala467Thr patients had a milder course and re-
mained ambulatory over decades, further confirming that the
major prognostic factor in POLG disease is epilepsy (Tzoulis,
2006). EEG monitoring in these patients may detect early signs
of epileptic activity, which would lead to the prescription of pre-
ventive antiepileptic therapy, although we are not aware of any
experimental data on its efficacy. The analysis of 27 Finnish pa-
tients homozygous for p.Trp748Ser showed similar results, namely,
that the disease prognosis depends predominantly on the course
of the epilepsy (Hakonen et al., 2007). Another study of 26 pa-
tients homozygous or compound heterozygous for either
p.Ala467Thr or p.Trp748Ser (Tzoulis, 2006) suggested a more
severe disease course and shorter survival in compound heterozy-
gous patients, although the age at onset was not significantly
different between the two groups. In keeping with our results,
the fatal prognosis was highly dependent on the occurrence of
epilepsy and liver failure, especially if patients were exposed to
sodium valproate (Tzoulis et al., 2006). The relative non-specificity
of the histological findings in children together with the severe
often fatal valproate toxicity indicates that POLG analysis should
precede sodium valproate therapy in paediatric patients with a
typical phenotype.
Peripheral neuropathy has been reported in all adult patients,
but only rarely in children, suggesting either that it develops later
in the disease course, unless it simply reflects that electrophysio-
logical investigations are not frequently performed in this age
group. In support of our findings, peripheral neuropathy has not
been reported in other series of children with POLG deficiency
(Hunter et al., 2011; Isohanni et al., 2011). Ataxia was present
in most of our cases (85%) and was not a discriminating factor
related to disease course or prognosis. Ataxia was largely related
to the presence of severe sensory neuropathy, and all patients
with sensory-axonal peripheral neuropathy had ataxia. The occa-
sional occurrence of ataxia without neuropathy and the presence
of cerebellar symptoms including nystagmus and dysarthria sug-
gest, however, that POLG-related ataxia may also be due to cere-
bellar damage. Our data suggest that both the peripheral and
central components of ataxia increase with age.
Pathogenic POLG mutations have been reported presenting in
similar ways to primary mitochondrial DNA disease [such as
MELAS, MERRF (Myoclonic Epilepsy with Ragged Red Fibres),
Kearns–Sayre Syndrome], reflecting without doubt the damaging
effect of the impaired mitochondrial DNA polymerase on mito-
chondrial DNA (Deschauer et al., 2007; Tzoulis and Bindoff,
2008; Bindoff, 2011). However, some frequent mitochondrial
DNA-related symptoms, such as diabetes mellitus, hearing loss
or cardiomyopathy were infrequent in our cohort of patients
with homozygous p.Ala467Thr. Cardiac abnormalities were only
noted in two cases and were minor, which is in contrast with the
frequent occurrence of MELAS-related diabetes and severe cardiac
disease (Kaufmann et al., 2011). It is conceivable that some tissues
(heart, pancreatic beta cells, inner ear) are less sensitive to POLG-
related damage than to single mitochondrial DNA point mutations.
Interestingly, none of the patients with homozygous
p.Ala467Thr had parkinsonism. There are some reports of extra-
pyramidal symptoms (parkinsonism, tremor, dystonia) in POLG-
related disease (Synofzik et al., 2010; Orsucci et al., 2011;
Hinnell et al., 2012). The role of POLG variants in sporadic idio-
pathic Parkinson disease has been intensively studied (Tiangyou
et al., 2006; Luoma et al., 2007; Eerola et al., 2010), and one
study suggested that POLG poly-Q alleles other than the con-
served 10Q allele may increase susceptibility to Parkinson’s disease
(Luoma et al., 2007; Eerola et al., 2010). However, no association
was detected between common POLG variants and sporadic idio-
pathic Parkinson’s disease (Tiangyou et al., 2006). In our series,
these symptoms were extremely rare (four cases of tremor, one of
blepharospasm and no parkinsonism), indicating that extrapyram-
idal symptoms are rare or possibly specific for mutations of the
polymerase domain (Luoma et al., 2005).
Histological (ragged red fibres, cytochrome c oxidase fibres),
biochemical (respiratory chain defect) and genetic abnormalities
(multiple mitochondrial DNA deletions, mitochondrial DNA
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depletion) in skeletal muscle were detected more frequently in
older age (Tables 3 and 4). There was no correlation between
muscle alterations and clinical severity. Muscle histology had the
highest detection rate (91%), followed by multiple mitochondrial
DNA deletions/depletion (60%), whereas biochemical respiratory
chain analysis was the least informative feature (54%). All patients
with progressive external ophthalmoparesis and/or myopathy had
abnormal muscle histology, although they did not always show
respiratory chain deficiency or mitochondrial DNA abnormalities,
confirming that the latter changes are not present in all patients
and are not prognostic, thus making their role controversial in the
routine diagnosis of POLG-related disease (Tang et al., 2011).
In this study, genetic analysis of 44 patients from different
Caucasian ethnic backgrounds confirmed a founder effect for
the p.Ala467Thr of this mutation, with all patients having an iden-
tical POLG haplotype, including the predicted promoter region
polymorphism. These results also exclude that changes in the pu-
tative predicted promoter region are responsible for the variable
clinical severity due to an effect on expression of the POLG pro-
tein. Increasing variability of chromosome 15 microsatellites was
detected in parallel with the distance from the POLG gene, indi-
cating that the p.Ala467Thr mutation is an ancient European foun-
der and occurred in a single common ancestor.
Comparison of the chromosomal haplotype blocks with age at
onset and phenotype revealed an apparent relationship between
the D15S127 marker and epilepsy (Fig. 4A). Further studies are
needed to define whether this result is biologically significant, or
related to the limited size of our cohort, and unknown confound-
ing factors.
We tested whether co-existing mutations in other genes acting
in concert with POLG in mitochondrial DNA maintenance may
contribute to the diverse phenotypic manifestation in our homo-
zygous p.Ala467Thr cohort. This possibility was suggested in one
patient who carried in addition to the homozygous p.Ala467Thr
mutation in POLG, also the heterozygous p.Val289Met mutation
in ANT1 (Galassi et al., 2008). The clinical presentation in this
patient evolved from progressive external ophthalmoparesis to a
severe neurological syndrome, comprising sensory and cerebellar
ataxia and peripheral neuropathy. Unusual for the homozygous
p.Ala467Thr, both parkinsonism and depression were found. We
detected no evidence of additional modifying factors in our ana-
lyses of the POLG2, PEO1 and ANT1 genes.
A protective effect of the U (UK) mitochondrial DNA haplotype
against the development of Parkinson’s disease has been reported
in Russian-Tatar population (Khusnutdinova et al., 2008). Suissa
et al. (2009) showed that a variant defining mitochondrial DNA
background ‘J’ significantly increased the transcriptional efficiency
and elevated mitochondrial DNA copy numbers in cybrid cells
compared with other genetic background. Haplogroups U and J
were suggested being more loosely coupled and therefore may be
associated with less reactive oxygen species production, which
could explain resistance to neurodegenerative disease
(Khusnutdinova et al., 2008). However, haplogroup associations
may be biased by the homogeneous ethnic background or the
limited number of cases. The distribution of mitochondrial DNA
haplogroups in our patient cohort was similar to what would be
expected from a western European population, thus indicating
that mitochondrial DNA haplogroup per se is not likely to influ-
ence the clinical presentation of the homozygous p.A467T muta-
tion. However, mitochondrial DNA haplogroup U was significantly
less frequent in patients with epilepsy, implying that being mito-
chondrial DNA haplogroup U may protect against developing epi-
lepsy and raise the possibility that haplogroup U neurons are less
prone to replication errors of mitochondrial DNA. We could not
detect any association between mitochondrial DNA background
and other clinical features, and whole mitochondrial DNA sequen-
cing in nine patients did not show any mitochondrial DNA variants
that could modify the phenotype (B. van den Bosch, unpublished
observation,). However, the number of patients was rather small
and a larger study should be performed to be able to draw solid
conclusions regarding the influence of other mitochondrial DNA
variants besides the haplogroup variants. Also, haplogroup associ-
ations may be biased by the homogeneous ethnic background or
the limited number of cases. Another possibility is that tissue-spe-
cific occurrence of mitochondrial DNA deletions, mitochondrial
DNA depletion or somatic point mutations may influence the clin-
ical course (Khusnutdinova et al., 2008). Our skeletal muscle data
do not support this in our cohort, however, suggesting that we
still have to consider other potential modifiers such as epigenetic
and environmental factors (Yu-Wai-Man et al., 2011).
In summary, we report the largest series of patients homozy-
gous for the POLG mutation p.Ala467Thr, and found that the
clinical presentation was almost as variable as in patients carrying
different pathogenic POLG mutations and that siblings have simi-
lar clinical presentation, suggesting that genetic or other environ-
mental or epigenetic factors may be important modifiers of the
disease course. We analysed both mitochondrial DNA haplotype
and gender and found that haplotype U or U/K may protect
against epilepsy and that females with p.Ala467Thr are more
likely to develop epilepsy.
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